Rocket
Premium
Excel Add-In
International
Tools
Dashboard
Screener
Spinoffs
IPOs
Register
Alerts
Sign In
Overview
Financials
News + Filings
IR Vault
Key Docs
Charts
Ownership
Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director comp.
CC transcript
EXELIXIS, INC. (EXEL)
Create:
Alert
All
|
News
|
Filings
Date Filed
Type
Description
08/23/2023
8-K
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/01/2023
8-K
Quarterly results
07/24/2023
8-K
Quarterly results
05/09/2023
8-K
Quarterly results
Docs:
"
Exelixis Announces First Quarter 2023 Financial Results and Provides Corporate Update - Total Revenues of $408.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $363.4 million -
"
05/08/2023
8-K
Quarterly results
04/13/2023
8-K
Quarterly results
03/22/2023
8-K
Other Events Interactive Data
03/20/2023
8-K
Quarterly results
02/07/2023
8-K
Quarterly results
Docs:
"
EXELIXIS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
"
01/09/2023
8-K
Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data
Docs:
"
Exelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023 – Cabozantinib franchise achieves approximately $1.4 billion in preliminary U.S. net product revenues for full year 2022, including approximately $375 million for fourth quarter 2022 –
"
12/15/2022
8-K
Quarterly results
11/01/2022
8-K
Quarterly results
09/02/2022
8-K
Other Events Interactive Data
08/09/2022
8-K
Quarterly results
Docs:
"
EXELIXIS ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
"
07/19/2022
8-K
Quarterly results
05/27/2022
8-K
Quarterly results
05/10/2022
8-K
Quarterly results
04/13/2022
8-K
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/23/2022
8-K
Other Events Interactive Data
02/17/2022
8-K
Quarterly results
Docs:
"
EXELIXIS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
"
01/10/2022
8-K
Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data
Docs:
"
Exelixis Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results, Provides 2022 Financial Guidance, and Outlines Key Priorities and Milestones for 2022 — Corporate priorities for 2022 include initial readout of up to three cabozantinib pivotal trials; initiation of pivotal trial program for XL092; expansion of clinical programs for XL092, XB002 and XL102; and multiple new development candidates from small molecule and biologics programs
"
12/17/2021
8-K
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/02/2021
8-K
Quarterly results
Docs:
"
EXELIXIS ANNOUNCES THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
"
08/05/2021
8-K
Quarterly results
Docs:
"
EXELIXIS ANNOUNCES SECOND QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
"
06/21/2021
8-K
Quarterly results
06/21/2021
8-K
Quarterly results
05/27/2021
8-K
Quarterly results
05/11/2021
8-K
Quarterly results
05/06/2021
8-K
Quarterly results
03/05/2021
8-K
Quarterly results
03/03/2021
8-K
Quarterly results
02/10/2021
8-K
Quarterly results
02/05/2021
8-K
Quarterly results
01/11/2021
8-K
Quarterly results
Next >>
Rocket Data Systems, Inc. © 2019 |
Contact Us
|
Data Disclaimer
|
Terms of Use
|
Privacy